Kleinklein is a research-focused startup that aims to address the challenges of chronic pain through tangible therapies and courses, as indicated by their slogan, "Researching chronic pain to offer tangible therapies and courses that help individuals and their loved ones reduce its impact and frequency." The company specializes in conducting thorough research on chronic pain and offers effective solutions, therapies, courses, and workshops. The support provided by Kleinklein extends to both affected individuals and their spouses, guiding them in taking actionable steps to reduce the intensity and frequency of pain episodes. Their efforts are particularly significant as chronic pain can significantly impact daily life, even in the absence of an underlying medical condition, with its effects sometimes visible on MRI scans. The pain can manifest in various forms, such as visceral or somatic pain, as well as nociceptive or neuropathic, profoundy affecting those it touches.
The most recent investment in Kleinklein amounts to €50.00K, in the form of a grant investment on 01 July 2016. This investment was provided by EASME - EU Executive Agency for SMEs. The lack of specific founding date and headquarters information suggests that Kleinklein is a relatively young and agile company that leverages research and innovative solutions to address a significant societal issue.
